July 2023
·
76 Reads
Positron emission tomography (PET) imaging of tau aggregation in Alzheimer’s disease (AD) is helping to map and quantify the in vivo progression of AD pathology. To date, no high-affinity 4-repeat (4R)-tau PET radiopharmaceutical for imaging non-AD tauopathies exists. Herein, the properties of analogues of a first-in-class 4R-tau lead, [ ¹⁸ F]OXD-2115, are described. Over 150 analogues of OXD-2115 were synthesized and screened for tau affinity in vitro against [ ³ H]OXD-2115, and in silico models were used to predict brain uptake. [ ¹⁸ F]OXD-2314 was identified as a selective, high-affinity non-AD tau PET radiotracer with favorable brain uptake, dosimetry, and radiometabolite profiles in rats and non-human primate and is being translated for first-in-human PET studies.